GLP-1 and Satiety: A Nutrition and Natural-Health Reference
Definition and Overview
Glucagon-like peptide-1 (GLP-1) is a 30-amino acid peptide hormone produced in the intestinal epithelial endocrine L-cells by differential processing of proglucagon, the gene which is expressed in these cells. GLP-1 is a gut-brain hormone that coordinates several prandial and post-prandial metabolic functions, including gastric emptying, incretin effect, and satiation.
GLP-1 plays a pivotal role in glucose homeostasis by enhancing insulin secretion, suppressing glucagon release, delaying gastric emptying, and acting on the central nervous system to regulate satiation and satiety. GLP-1 has long been identified and validated as a biomarker peptide for satiation and satiety under physiological conditions.
Satiation refers to the process occurring during a meal event that prompts eating termination and is associated with meal size, while satiety refers to the process occurring between meals that influences when the next eating episode begins. These are related but distinct processes, and GLP-1 is recognized as having a role in both.
Body Systems Involved
The Gastrointestinal Tract and L-Cells
GLP-1 is mainly synthesized and secreted by enteroendocrine L-cells of the gastrointestinal tract. GLP-1 is released in response to meal ingestion, generally within 15–30 minutes, and enhances insulin secretion from pancreatic beta-cells, which contributes to normalizing the postprandial glycemic response. GLP-1 is extremely rapidly metabolized and inactivated by the enzyme dipeptidyl peptidase IV (DPP-IV) even before the hormone has left the gut, raising the possibility that the actions of GLP-1 are transmitted via sensory neurons in the intestine and the liver expressing the GLP-1 receptor.
The Pancreas
The main actions of GLP-1 are to stimulate insulin secretion (i.e., to act as an incretin hormone) and to inhibit glucagon secretion, thereby contributing to limiting postprandial glucose excursions. The activities of GLP-1 include stimulating insulin gene expression and biosynthesis, improving β-cell proliferation, exogenesis, and survival, and it prevents β-cell apoptosis induced by a variety of cytotoxic agents.
The Central Nervous System
GLP-1 was discovered in the brain, and early studies indicated an effect on appetite and food intake, with subsequent more detailed studies confirming these effects after intracerebroventricular administration of low doses of the peptide. Neurons of the hindbrain found in the nucleus tractus solitarius (NTS) secrete GLP-1 and activate hypothalamic neurons of the paraventricular nucleus (PVN), resulting in satiety.
Human neuroimaging studies demonstrate that GLP-1 receptor agonists influence brain activity during food cognition, supporting a role in pre-ingestive satiation. The satiety effect of GLP-1 may involve both meal entero-enteric reflexes and across-meal central signaling mechanisms to mediate changes in appetite and promote satiety.
The Vagus Nerve
Intestinal GLP-1 is an endogenous satiation signal, whose eating effects are primarily mediated by vagal afferents. Studies in experimental animals revealed that effects of GLP-1 on secretions of insulin and glucagon, gastric emptying, and appetite involve activation of the vagus nerve.
Adipose Tissue and Other Extrapancreatic Targets
In extrapancreatic tissues, GLP-1 suppresses hunger, delays gastric emptying, acts as an ileal brake, and increases glucose uptake. GLP-1 also regulates appetite in a manner similar to hormones such as peptide tyrosine-tyrosine (PYY) and leptin, to promote fullness and reduce energy intake.
GLP-1 Secretion: Physiological Triggers
The secretion of GLP-1 is partly mediated by nutrient binding to G-protein-coupled receptors (GPCRs) or by absorption via membrane transporters, which are expressed by enteroendocrine L-cells in the gastrointestinal tract. Its secretion is partly mediated by the direct nutrient sensing by G-protein coupled receptors which specifically bind to monosaccharides, peptides and amino acids, monounsaturated and polyunsaturated fatty acids, as well as to short chain fatty acids.
Whereas the extent of GLP-1 secretion is principally mediated by meal size (in order to reach the distal gut), the nutrient composition of a meal might also be influential for maximizing L-cell receptor activation and transporter utilization.
Contributing and Associated Factors
Obesity and Metabolic Dysregulation
GLP-1 has several effects on various organ systems, among which the most relevant is the reduction of appetite and food intake, leading to long-term weight loss. GLP-1 secretion from the gut seems to be impaired in obese subjects, suggesting a role in the pathophysiology of obesity. Based on the available human evidence, meal-induced intestinal GLP-1 secretion is reduced, but the anorexigenic effect of GLP-1 is maintained in obese humans.
GLP-1 secretion may be lower in adults with obesity/overweight or type 2 diabetes mellitus than in those with normal glucose tolerance, but these findings are inconsistent.
Gut Microbiota Composition
Gut microbiota exert influence on gastrointestinal mucosal permeability, bile acid metabolism, short-chain fatty acid synthesis, dietary fiber fermentation, and farnesoid X receptor/TGR5 signal transduction. Changes in gut microbiota composition and function have been observed in obesity and type 2 diabetes, and the function and rhythm of GLP-1 have also been affected in subjects with obesity or T2D.
Sleep Disruption
Previous experiments have demonstrated that acute sleep loss impairs glucose homeostasis and increases food intake in humans. The incretin hormone GLP-1 enhances postprandial insulin secretion and promotes satiety. Hypothesizing that the detrimental metabolic effects of sleep curtailment imply alterations in GLP-1 signaling, researchers investigated 24-hour serum total GLP-1 concentrations during total sleep deprivation and a normal sleep/wake cycle in 12 healthy young men. Sleep restriction to 4 hours per night in healthy participants resulted in lower GLP-1 levels in the afternoon in women; in addition, total sleep deprivation in healthy participants resulted in a delayed GLP-1 response to breakfast.
Bariatric Surgery
Several studies have shown that Roux-en-Y gastric bypass increases GLP-1 blood concentrations up to fourfold 6 months to 1 year after the procedure. This increase in GLP-1 concentrations is associated with improvements in dietary choices and intake, further excess weight loss, improved glycaemic control, and often T2D resolution.
Macronutrients and GLP-1 Secretion
Protein
Protein is considered the most satiating of the macronutrients, and is often associated with weight loss, which could be mediated in part by protein-induced stimulation of appetite regulatory hormones, including GLP-1. Traditionally, fat and carbohydrate were thought to be the most potent stimulants of GLP-1 release, but this has subsequently been challenged by research comparing protein ingestion with carbohydrate and fat in humans.
Meals high in protein induce greater intermeal satiety than meals high in fat and carbohydrates. Researchers studied the gut hormone response and subsequent food intake after breakfasts high in protein, carbohydrate, or fat, controlled for volume, calories, and appearance, in eight healthy volunteers participating in a randomized three-way crossover study. They found that a high-protein meal resulted in increased secretion of PYY and GLP-1.
In participants who were overweight or had impaired glucose tolerance, a high-protein diet (40% carbohydrates, 30% fat, 30% protein) resulted in greater postprandial GLP-1 secretion both during an oral glucose tolerance test and a mixed meal tolerance test when compared with a high-carbohydrate diet (55% carbohydrates, 30% fat, 15% protein).
Direct stimulation of enteroendocrine cells by amino acids has been proposed as a trigger factor for PYY and GLP-1 secretion. The calcium-sensing receptors (CaSR) have been shown to act as l-amino acid sensors in the L-cells. Therefore, activation of the CaSR following exposure to a wide range of amino acids in the diet can lead to GLP-1 and PYY secretion from the gut. Moreover, glutamine has been shown to stimulate GLP-1 secretion through increasing calcium and cAMP in ex-vivo L-cells.
Human and animal studies have revealed that dietary proteins and peptides have a potent effect on stimulating GLP-1 secretion. Specific protein forms that have been studied include whey, casein, gluten, and soy protein. Whey and casein, both proteins found in cow's milk, increased GLP-1 secretion; both gluten and soy protein similarly increased GLP-1 secretion.
Dietary Fats
Previous human studies demonstrated an olive oil-rich meal induced a higher GLP-1 response than a butter-rich meal, suggesting that unsaturated fatty acids are more effective stimulators of GLP-1 secretion than saturated fatty acids.
Meals high in protein or high in monounsaturated fat may increase GLP-1 response. In humans, a Mediterranean diet rich in olive oil led to higher post-meal GLP-1 levels, improved insulin sensitivity, and lower fasting and post-meal blood glucose levels compared to a diet high in saturated fats. The evidence for MUFAs is, however, derived from a limited number of human studies, and the dose-response relationship is not yet fully established.
Carbohydrates
The release of GLP-1 is primarily stimulated by macronutrients such as glucose and fatty acids, which are nutritionally indispensable; however, excessive intake of sugar and fat is responsible for the development of obesity and diabetes. The degree of glucose tolerance, separately and in combination with the nutrient composition and type of carbohydrates, influences carbohydrate-stimulated GLP-1 secretion.
Protein and Calcium Synergy
Emerging evidence suggests that the synergy of protein and calcium could act as a potent secretagogue of GLP-1. In the most recent human study, this synergy produced some of the highest reported concentrations of GLP-1 following physiological ingestion to date. This is particularly interesting given that calcium does not provide energy, and therefore GLP-1 release is relatively greater despite no additional energy provision.
Dietary Fiber, Prebiotics, and the Gut Microbiota Axis
Bacterial metabolites include the short chain fatty acids (SCFAs) acetate, propionate, and butyrate, which are the most abundant SCFAs in the human body and the most abundant anions in the colon. SCFAs are made from fermentation of dietary fiber and resistant starch in the gut.
Both in vitro and in vivo studies have demonstrated that SCFAs increase the release of PYY and GLP-1 from L-cells and promote leptin hormone satiation in adipose tissue via G-protein receptors such as GPR41 and GPR43. Studies in vitro and in vivo showed that SCFAs are potent secretagogues for GLP-1 and PYY that increase satiety feeling through the gut-brain axis. As a consequence, they might indirectly reduce appetite and consequent food intake, thus preventing body weight gain, a well-known risk factor for T2D.
A notable clinical finding comes from a 12-month fiber intervention trial: randomizing hyperinsulinemic subjects into a high-fiber wheat cereal diet against a low-fiber cereal diet, no significant differences were found until 6 months into the study. Only at 9 months were acetate and butyrate concentrations higher for participants on the high-fiber than the control diet. Meanwhile, at the end of the trial (12 months), authors detected an increase in GLP-1 secretion. Therefore, although without an immediate effect, this evidence suggested a contribution of fiber to a reduced risk for T2D.
Foods rich in these nutrients, such as high-fiber grain products, nuts, avocados, and eggs, also seem to influence GLP-1 secretion and may thus promote associated beneficial outcomes in healthy individuals as well as individuals with type 2 diabetes or with other metabolic disturbances.
Whole Dietary Patterns
Clinical guidelines recommend carbohydrate intake from high-fiber foods such as vegetables, fruit, legumes, and whole grains, while limiting saturated fat intake and promoting that of MUFAs and omega-3 PUFAs, all of which have been associated to different extents with increased GLP-1 secretion.
The addition of foods with a high protein, MUFA, and fiber content, such as almonds (30.0 to 90.0 g) or pistachios (28.0 to 85.0 g) to a high-carbohydrate meal has also been shown to improve postprandial glycemic responses in a dose-dependent manner.
Nutrients, Herbs, and Natural Ingredients
Omega-3 Polyunsaturated Fatty Acids
Scientific evidence: Evidence from preclinical and clinical studies indicates that omega-3 polyunsaturated fatty acids may enhance the metabolic benefits of GLP-1 receptor agonists and attenuate lean mass loss, primarily via anti-inflammatory pathways and modulation of protein synthesis. Through interaction with free fatty acid receptors (FFARs), particularly FFAR4, they contribute to macrophage polarization toward the anti-inflammatory M2 phenotype, thereby improving glycogen synthesis and insulin signaling. Fish oil and flaxseed oil, which are sources of alpha-linolenic acid, increased FFAR4 expression in rodents' colon and decreased the expression of the pro-inflammatory tumour necrosis factor alpha (TNFα). This evidence is largely preclinical; human data specifically on omega-3 effects on endogenous GLP-1 secretion remain limited.
Berberine
Traditional use: Berberine is an alkaloid derived from the roots and bark of several plants, including Coptis chinensis (goldthread), Berberis vulgaris (barberry), and goldenseal. Berberine is the main component of a number of particularly bitter medicinal plants, such as Coptis Rhizome. In Traditional Chinese Medicine (TCM), preparations from these plants have long been used for conditions described as "heat and damp" patterns, including what would now be recognized as metabolic dysregulation and gastrointestinal disorders. Coptis was historically decocted and administered as a tea or herbal formula.
Scientific evidence (in vitro and animal): Previous studies revealed that berberine-mediated GLP-1 secretion was a possible mechanism for berberine exerting beneficial effects on hyperglycemia. Research was designed to ascertain whether berberine-induced secretion of GLP-1 was related with activation of bitter taste receptors expressed in the gastrointestinal tract. The results demonstrated that berberine stimulated GLP-1 secretion via activation of gut-expressed bitter taste receptors in a PLC-dependent manner. Out of six berberine metabolites, berberrubine and palmatine significantly increased the production and glucose-stimulated secretion of GLP-1 in GLUTag cells.
Scientific evidence (clinical): A limited number of preclinical studies suggest that berberine may modestly increase endogenous GLP-1 secretion from intestinal L-cells, potentially through effects on gut microbiota or direct stimulation of enteroendocrine cells. However, these findings remain preliminary, inconsistent across studies, and have not been robustly demonstrated in well-designed human clinical trials. Meta-analyses of berberine trials show modest reductions in hemoglobin A1c (approximately 0.5–0.7%) and fasting glucose, with variable effects on body weight, though many studies have methodological limitations and high heterogeneity. Direct measurement of GLP-1 as a primary endpoint in human berberine trials remains lacking.
Curcumin (Turmeric, Curcuma longa)
Traditional use: Turmeric has been used for millennia in Ayurvedic and traditional South Asian medicine as a culinary spice and medicinal preparation. In Ayurveda, it was used for digestive complaints, inflammatory conditions, and general metabolic balance, often as a paste, decoction, or incorporated into food. Its use in traditional Chinese medicine parallels this, where it is referred to as jianghuang.
Scientific evidence (in vitro and animal): Curcumin, a yellow pigment isolated from the rhizomes of Curcuma longa, significantly increases GLP-1 secretion in GLUTag cells. The significant increase in GLP-1 secretion by curcumin involved the Ca²⁺-Ca²⁺/calmodulin-dependent kinase II pathway, and was independent of extracellular signal-regulated kinase, PKC, and the cAMP/PKA-related pathway. Glucose tolerance was significantly improved in rats after pre-administered curcumin (1.5 mg/kg) followed by intraperitoneal glucose injections via stimulation of GLP-1 secretion and the induction of insulin secretion. In GLUTag cells, curcumin-induced GLP-1 secretion was associated with G protein-coupled receptor (GPR) 40/120.
Curcumin amplifies L-cell number to promote GLP-1 secretion in obese mice. The findings suggest that curcumin may act as a natural TGR5 agonist and FXR antagonist to improve obesity by enhancing GLP-1 release from L-cell expansion via the gut microbiota-bile acids-TGR5/FXR axis.
Limitations: The evidence for curcumin-induced GLP-1 secretion is predominantly derived from cell-line studies (GLUTag, STC-1) and animal models. Robust human clinical trials specifically measuring GLP-1 as a primary endpoint are not yet available in the published literature. Curcumin shows antiglycemic effects in animals, but curcumin is chemically unstable at physiological pH, and its oxidative degradation products may contribute to its effects. This instability further complicates direct translation to human oral supplementation.
Quercetin and Flavonoids
Traditional use: Quercetin is a flavonol found abundantly in onions, apples, capers, and tea. Flavonoid-rich plants such as elderberry, buckwheat, and various medicinal herbs have been used in European, Asian, and indigenous herbal traditions for metabolic and digestive support, though these uses predated knowledge of GLP-1 as a mechanism.
Scientific evidence (in vitro and animal): Studies in enteroendocrine cell models have shown that dietary peptides, amino acids, and phytochemicals, such as quercetin, can directly stimulate GLP-1 secretion. Several flavonoids have been shown to enhance GLP-1 secretion in intestinal cell models and tissues, leading to increased plasma GLP-1 concentrations in animal studies. Most animal experiments indicate improved glucose tolerance alongside elevated plasma GLP-1 levels. Studies using enteroendocrine cell models such as murine GLUTag and human NCI-H716 cells, curcumin, delphinidin 3-rutinoside, ginsenoside metabolite Rg3, hispidulin, and isoquercitrin demonstrated stimulatory effects on GLP-1 secretion. Human Caco2 cells were also used to illustrate EGCG-induced GLP-1 secretion.
Limitations: The vast majority of evidence for flavonoids and GLP-1 secretion remains in vitro or animal-based. Translation to human physiology is uncertain, particularly given bioavailability considerations for flavonoids after oral intake. Well-controlled human clinical trials with GLP-1 as a primary measured outcome are lacking for most individual flavonoids.
Bitter Melon (Momordica charantia)
Traditional use: Bitter gourd (Momordica charantia) is a common tropical vegetable that has also been used to manage diabetes in oriental traditional medicine. It has been consumed as a food and medicinal preparation in South Asian, Southeast Asian, Chinese, and Caribbean traditional systems, typically as a juice, cooked vegetable, or decoction of the fruit or leaves.
Scientific evidence: There is evidence showing that T2R bitter taste receptors are expressed in enteroendocrine cells in the gut. A functionally compromised TAS2R bitter taste receptor negatively impacts glucose homeostasis. Stimulation of NCI-H716 cells with a TAS2R ligand elicited a dose-dependent secretion of GLP-1 from this human enteroendocrine cell line. Evidence from human intervention trials specifically measuring GLP-1 as an endpoint remains limited and methodologically heterogeneous. The available clinical evidence is insufficient to draw firm conclusions about the magnitude of effect in humans.
Tea Polyphenols (Green Tea, EGCG)
Traditional use: Green tea (Camellia sinensis) has been consumed for thousands of years in East Asian cultures, particularly China and Japan, for its perceived health-promoting properties. Traditional use included support for digestion and metabolic function, with preparations typically made as an infusion of dried tea leaves.
Scientific evidence: Certain herbal-based constituents, including tea, berberine, curcumin, cinnamon, wheat, soybean, resveratrol, and gardenia, have been found to exert an influence on GLP-1 release in studies. The evidence for green tea's effect on GLP-1 derives primarily from cell-line and animal models. Human Caco2 cells were used to illustrate EGCG-induced GLP-1 secretion. Human clinical data with GLP-1 secretion as a primary endpoint are sparse, and the extent to which green tea polyphenol consumption in typical dietary amounts meaningfully modulates endogenous GLP-1 in humans has not been definitively established.
Cinnamon (Cinnamomum spp.)
Traditional use: Cinnamon bark has been used in Ayurvedic, Chinese, and Middle Eastern traditional medicine systems for digestive complaints and as a warming spice with reported effects on blood sugar. Preparations typically include cinnamon sticks or ground bark in food and as teas or decoctions.
Scientific evidence: Some evidence suggests that natural products may have modulatory effects on GLP-1 expression and secretion, and certain herbal-based constituents including cinnamon can exert an influence on GLP-1 release. Available evidence is predominantly from in vitro and animal studies. Cinnamon has been included in reviews of natural GLP-1 modulators, but its clinical evidence for specifically increasing endogenous GLP-1 in humans remains preliminary and methodologically limited.
Resveratrol
Traditional use: Resveratrol is a polyphenol found in grape skins, red wine, and certain berries. Traditional use is not specific to resveratrol as an isolated compound; rather, grape- and berry-based preparations have long featured in Mediterranean and East Asian herbal traditions for metabolic and cardiovascular support.
Scientific evidence: Some evidence suggests that natural products may have modulatory effects on GLP-1 expression and secretion, and resveratrol has been identified among herbal-based constituents that can exert an influence on GLP-1 release. As with other polyphenols, the evidence for resveratrol's GLP-1-modulating effects is primarily preclinical, and well-controlled human trials with GLP-1 secretion as an endpoint are limited.
Inulin, Fructooligosaccharides (FOS), and Arabinoxylan-Oligosaccharides
Traditional use: Prebiotic fibers are not traditionally isolated compounds; rather, FOS-rich foods such as chicory, Jerusalem artichoke, onion, garlic, and leek have been dietary staples across European, Asian, and other food cultures, with their digestive benefits implicitly recognized.
Scientific evidence: In recent years, there has been a growing interest in the effect nutrients may have on GLP-1 secretion; some frequently studied dietary constituents include monounsaturated fatty acids, fructooligosaccharides, and glutamine. A study investigated the effect of a 12-week prebiotic intervention with 15 g/day wheat bran extract arabinoxylan-oligosaccharide on meal-stimulated GLP-1 secretion in 48 participants with normal glucose tolerance. Compared with the placebo group, the early postprandial GLP-1 response was decreased in the prebiotic group after consumption of a solid test meal. Results for prebiotic interventions on GLP-1 secretion in human trials have been mixed, and the overall evidence base is still developing.
Dietary and Lifestyle Factors
Meal Composition and Macronutrient Order
GLP-1 is one of two incretins secreted from the gut in response to ingestion of various nutrients (e.g., carbohydrate, protein, and fat), and stimulates insulin secretion from pancreatic β-cells glucose-dependently. In addition, GLP-1 suppresses glucagon secretion from pancreatic α-cells and delays gastric emptying, thereby ameliorating postprandial glucose excursion. Emerging research in meal sequencing suggests that the order in which food groups are consumed within a meal may also influence incretin hormone secretion and postprandial glucose profiles, though this remains an active area of investigation.
High-Fiber Dietary Patterns
Compared to ready-to-eat breakfast cereals, oatmeal increased fullness, and reduced hunger, desire to eat, as well as subjective prospective food intake, and decreased energy intake at the following meal. Dietary fiber is resistant to digestive enzymes in the gut, which modulates the anaerobic intestinal microbiota and promotes SCFA production. Sustained, rather than acute, dietary fiber intake appears necessary to produce measurable increases in GLP-1; one clinical trial required 12 months of high-fiber intake before significant changes were detected.
Mediterranean and Plant-Rich Dietary Patterns
A Mediterranean diet rich in olive oil led to higher post-meal GLP-1 levels, improved insulin sensitivity, and lower fasting and post-meal blood glucose levels compared to a diet high in saturated fats. The convergence of high fiber, MUFA-rich foods, protein diversity, and polyphenol content in the Mediterranean dietary pattern creates a nutritional environment broadly supportive of endogenous GLP-1 secretion, as assessed in a limited number of human studies.
Exercise
In a randomized trial, 52 abdominally obese non-diabetic men and women were assigned to 12 weeks of endurance exercise or no exercise, with changes in glycemic control, glucagon, and GLP-1 secretion as endpoints. There was no change in gastric emptying rate in any of the four groups following the intervention. The relationship between acute and chronic exercise and endogenous GLP-1 secretion remains incompletely understood, with conflicting results across studies depending on exercise type, duration, and population characteristics.
Sleep and Circadian Factors
Epidemiological observations indicate that short sleep is associated with an increased risk to develop obesity and type 2 diabetes. Experimental studies have provided evidence that acute sleep loss increases food intake and impairs glucose tolerance and insulin sensitivity. Research suggests that both total sleep deprivation and chronic short sleep can alter GLP-1 dynamics, delaying the postprandial GLP-1 peak or reducing afternoon GLP-1 levels, though the clinical magnitude of these effects and their causal role in metabolic disease remain areas of active study.
Evidence Strength: Summary
- Robust human evidence: Meal size and macronutrient content (especially protein) stimulating GLP-1 secretion; dietary fiber and SCFA production over prolonged intervention; GLP-1's satiety and food-intake-reducing effects in controlled clinical and crossover trials.
- Moderate human evidence: MUFAs (olive oil) vs. saturated fats on postprandial GLP-1; high-protein diets vs. high-carbohydrate diets on GLP-1 responses; protein-calcium synergy as a potent GLP-1 secretagogue.
- Preliminary/inconsistent human evidence: Mediterranean dietary patterns; prebiotic fiber interventions; sleep deprivation and GLP-1 dynamics; exercise training effects on GLP-1.
- Preclinical (in vitro/animal) evidence only, with limited or absent human clinical data: Curcumin, quercetin and most individual flavonoids, EGCG/green tea catechins, resveratrol, and cinnamon on GLP-1 secretion.
- Berberine: Preliminary preclinical evidence for increased endogenous GLP-1 secretion; findings remain preliminary, inconsistent across studies, and not yet robustly demonstrated in well-designed human clinical trials.
- Bitter melon: Mechanistic plausibility via bitter taste receptor activation in cell-line models; human trial evidence for GLP-1 as a primary endpoint is sparse.
References
Go back